{"id":"NCT01333592","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"Long-term Study of KAD-1229 in Type 2 Diabetes Patients","officialTitle":"A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":null,"primaryCompletion":"2012-08","completion":"2012-11","firstPosted":"2011-04-12","resultsPosted":"2014-11-24","lastUpdate":"2014-12-15"},"enrollment":136,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"KAD-1229","otherNames":[]}],"arms":[{"label":"KAD-1229","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.","primaryOutcome":{"measure":"Incidences of Adverse Events","timeFrame":"52 weeks","effectByArm":[{"arm":"KAD-1229 / DPP-4 Inhibitors","deltaMin":48,"sd":null},{"arm":"KAD-1229 / Biguanides","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":67},"commonTop":["Nasopharyngitis","Î³-glutamyltransferase increase","Bronchitis","Upper respiratory tract inflammation","Pharyngitis"]}}